https://faqsir.com/company/curatis-holding-ag/feed<![CDATA[Curatis Holding AG — Announcements]]>Curatis Holding AG (SIX:CURN) announcements published on FAQSIR. AI-generated content. Paid-for issuer communication. Not investment advice. Published in partnership with Curatis Holding AG. Curatis Holding AG pays FAQSIR a subscription fee for this page.2026-10-14T12:22:08+00:00<![CDATA[Curatis reports 51% first-half revenue increase and progress on corticorelin programme]]>https://faqsir.com/3330AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:21:56+00:002026-10-14T12:21:56+00:00<![CDATA[Curatis raises 2026 revenue growth guidance to approximately 40%]]>https://faqsir.com/3327AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:21:27+00:002026-10-14T12:21:27+00:00<![CDATA[Curatis Holding AG shareholders approve all board proposals at AGM]]>https://faqsir.com/3328AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:21:28+00:002026-10-14T12:21:28+00:00<![CDATA[Curatis agrees CHF 3.0 million convertible placement, subject to closing conditions]]>https://faqsir.com/3326AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:21:23+00:002026-10-14T12:21:23+00:00<![CDATA[Curatis reports 2025 revenue growth as corticorelin programme advances]]>https://faqsir.com/3332AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:22:08+00:002026-10-14T12:22:08+00:00<![CDATA[Curatis and Neupharma announce Japan licensing agreement for corticorelin]]>https://faqsir.com/3331AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:22:03+00:002026-10-14T12:22:03+00:00<![CDATA[Curatis agrees CHF 1.2 million convertible placement, subject to conditions]]>https://faqsir.com/3329AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:21:29+00:002026-10-14T12:21:29+00:00